1153509-29-5

Basic information

• Product Name: 1-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)-N-methylmethanamine
• Synonyms: 1-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)-N-methylmethanamine
• CAS NO: 1153509-29-5
• Molecular Weight: 229.325
• Mol File: 1153509-29-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)-N-methylmethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)-N-methylmethanamine(1153509-29-5)
• EPA Substance Registry System: 1-(1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)-N-methylmethanamine(1153509-29-5)

Safety Data

• Hazardous Substances Data: 1153509-29-5(Hazardous Substances Data)

Upstream product

• 100-44-7 benzyl chloride 
• 50-00-0 formaldehyd 
• 1134-81-2 1-benzyl-3,5-dimethyl-1H-pyrazole 
• 593-51-1 methylamine hydrochloride 
• 67-51-6 3,5-dimethyl-1H-pyrazole 

Downstream Products

• 1280194-01-5 1-(((1-benzyl-3,5-dimethyl-1H-pyrazol-4-yl)methyl)(methyl)amino)-3-(4-ethoxyphenoxy)propan-2-ol 
• 1227743-61-4 1-(((1-Benzyl-3,5-dimethyl-1H-pyrazol-4-yl)methyl)(methyl)amino)-3-phenoxypropan-2-ol 

Relevant articles and documents

Discovery of novel small molecule TLR4 inhibitors as potent anti-inflammatory agents

Toll-like receptor 4 (TLR4) initiates innate immune response to release inflammatory cytokines and has been pathologically linked to variety of inflammatory diseases. Recently, we found that Carvedilol, as the classic anti-heart failure and anti-inflammatory clinic drug, could inhibit the TLR4 signaling in the TLR4 overexpressed cells. Herein, we have designed and synthesized a small library of novel Carvedilol derivatives and investigated their potential inhibitory activity. The results indicate that the most potent compound 8a (SMU-XY3) could effectively inhibited TLR4 protein and the LPS triggered alkaline phosphatase signaling in HEK-Blue hTLR4 cells. It down regulated the nitric oxide (NO) in both RAW264.7 cells and BV-2 microglial cells, in addition to blocking the TNF-α signaling in ex-vivo human peripheral blood mononuclear cells (PBMC). More interestingly, 8a shows higher affinity to hyperpolarization-activated cyclic nucleotide-gated 4 (HCN4) over HCN2, which probably indicates the new application of TLR4 inhibitor 8a in heart failure, coronary heart disease, and other inflammatory diseases.